Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

Cancer Treatment Reviews

Volumn 50, Issue , 2016, Pages 1-8

  Franceschini, D ^a   Franzese, C ^a   Navarria, P ^a   Ascolese, A M ^a   De Rose, F ^a   Del Vecchio, M ^b   Santoro, A ^a,c   Scorsetti, M ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c HUMANITAS UNIVERSITY   (Italy)

Author keywords

Checkpoint inhibitors; Immunotherapy; Radiation therapy; Stereotactic radiosurgery

Indexed keywords

IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL STUDY; HUMAN; MELANOMA METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRECLINICAL STUDY; RADIATION DOSE; RADIATION NECROSIS; REVIEW; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BRAIN RADIOTHERAPY; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOSURGERY; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGNOSIS; RADIOSURGERY; SKIN NEOPLASMS;

EID: 84983468144     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.08.003     Document Type: Review

References (99)

1. [1] Ahluwalia, M.S., Vogelbaum, M.V., Chao, S.T., et al. Brain metastasis and treatment. F1000 Prime Reports, 6, 2014, 114.
2. [2] Sampson, J.H., Carter, J.H. Jr, Friedman, A.H., Seigler, H.F., Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88 (1998), 11–20.
3. [3] Bafaloukos, D., Gogas, H., The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30:6 (2004), 515–520.
4. [4] Staudt, M., Lasithiotakis, K., Leiter, U., Meier, F., Eigentler, T., Bamberg, M., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102 (2010), 1213–1218.
5. [5] Skibber, J.M., Soong, S.J., Austin, L., Balch, C.M., Sawaya, R.E., Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3 (1996), 118–123.
6. [6] Gibney, G.T., Forsyth, P.A., Sondak, V.K., Melanoma in the brain: biology and therapeutic options. Melanoma Res 22 (2012), 177–183.
7. [7] Fife, K.M., Colman, M.H., Stevens, G.N., et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22 (2004), 1293–1300.
8. [8] Ramakrishna, N., Margolin, K.A., Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book, 2013, 399–403.
9. [9] Ahluwalia, M.S., Winkler, F., Targeted and immunotherapeutic approaches in brain metastases. Am Soc Clin Oncol Educ Book, 2015, 67–74.
10. [10] Patchell, R.A., Tibbs, P.A., Walsh, J.W., Dempsey, R.J., Maruyama, Y., Kryscio, R.J., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:8 (1990), 494–500, 10.1056/NEJM199002223220802.
11. [11] Vecht, C.J., Haaxma-Reiche, H., Noordijk, E.M., Padberg, G.W., Voormolen, J.H., Hoekstra, F.H., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 33:6 (1993), 583–590.
12. [12] Fonkem, E., Uhlmann, E.J., Floyd, S.R., et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 12 (2012), 1207–1215.
13. [13] Kocher, M., Soffietti, R., Abacioglu, U., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:2 (2011), 134–141.
14. [14] Fertil, B., Malaise, E.P., Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11 (1985), 1699–1707.
15. [15] la Fuente, M., Beal, K., Carvajal, R., Kaley, T.J., Whole-brain radiotherapy in patients with brain metastases from melanoma. CNS Oncol 3 (2014), 401–406.
16. [16] Morris, S.L., Low, S.H., A'Hern, R.P., et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 91 (2004), 829–833.
17. [17] Tsao, M.N., Lloyd, N., Wong, R.K., et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev, 4, 2012, CD003869.
18. [18] Chang, E.L., Wefel, J.S., Hess, K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10 (2009), 1037–1044.
19. [19] Aoyama, H., Shirato, H., TagoM, M., Nakagawa, K., Toyoda, T., Hatano, K., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:21 (2006), 2483–2491, 10.1001/jama.295.21.2483.
20. [20] Brown, P.D., Asher, A.L., Ballman, K.V., et al. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patient with 1–3 brain metastases. Proc. American Society of Clinical Oncology, 2015 Abstract LBA#4.
21. [21] Patchell, R.A., Tibbs, P.A., Regine, W.F., Dempsey, R.J., Mohiuddin, M., Kryscio, R.J., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:17 (1998), 1485–1489.
22. [22] Chang, W.S., Kim, H.Y., Chang, J.W., Park, Y.G., Chang, J.H., Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?. J Neurosurg 113:suppl (2010), 73–78.
23. [23] Ajithkumar, T., Parkinson, C., Fife, K., Corrie, P., Jefferies, S., Evolving treatment options for melanoma brain metastases. Lancet Oncol 16 (2015), e486–e497.
24. [24] Manon, R., O'Neill, A., Knisely, J., et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an eastern cooperative oncology group study (E 6397). J Clin Oncol 23:34 (2005), 8870–8876.
25. [25] Andrews, D.W., Scott, C.B., Sperduto, P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:9422 (2004), 1665–1672.
26. [26] Samlowski, W.E., Jensen, R.L., Shrieve, D.C., Multimodality management of brain metastases in metastatic melanoma patients. Expert Rev Anticancer Ther 7:12 (2007), 1699–1705.
27. [27] Boogerd, W., de Gast, G.C., Dalesio, O., Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?. Cancer 109:2 (2007), 306–312.
28. [28] Patel, P.M., Suciu, S., Mortier, L., et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:10 (2011), 1476–1483.
29. [29] Lockman, P.R., Mittapalli, R.K., Taskar, K.S., Rudraraju, V., Gril, B., Bohn, K.A., et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:23 (2010), 5664–5678.
30. [30] Saas, P., Walker, P.R., Hahne, M., et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J Clin Invest 99 (1997), 1173–1178.
31. [31] Larocque, D., Sanderson, N.S., Bergeron, J., et al. Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci USA 107 (2010), 14443–14448.
32. [32] Guirguis, L.M., Yang, J.C., White, D.E., et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 25 (2002), 82–87.
33. [33] Engelhardt, B., The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr Pharm Des 14 (2008), 1555–1565.
34. [34] Prins, R.M., Vo, D.D., Khan-Farooqi, H., et al. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol 177 (2006), 8448–8455.
35. [35] Heller, K.N., Pavlick, A.C., Hodi, F.S., et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Proc Am Soc Clin Oncol, 29(suppl), 2011 abstr 8581.
36. [36] Queirolo, P., Spagnolo, F., Ascierto, P.A., et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118 (2014), 109–116.
37. [37] Lebbe, C., McDermott, D.F., Robert, C., et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial [abstract]. Ann Oncol, 21(Suppl. 8), 2010, 401.
38. [38] Di Giacomo, A.M., Ascierto, P.A., Pilla, L., et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:9 (2012), 879–886.
39. [39] Weber, J.S., Amin, A., Minor, D., et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:6 (2011), 530–534.
40. [40] Long, G.V., Trefzer, U., Davies, M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 1087–1095.
41. [41] Kefford, R.M.M., Arance, A., Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Presented at: Society for Melanoma Research Congress; Philadelphia, PA, 2013.
42. [42] Stone, H.B., Peters, L.J., Milas, L., Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 63 (1979), 1229–1235.
43. [43] Apetoh, L., Ghiringhelli, F., Tesniere, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007), 1050–1059.
44. [44] Apetoh, L., Tesniere, A., Ghiringhelli, F., et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 68 (2008), 4026–4030.
45. [45] Lee, Y., Auh, S.L., Wang, Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114 (2009), 589–595.
46. [46] Demaria, S., Kawashima, N., Yang, A.M., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:2 Pt 1 (2005), 728–734.
47. [47] Demaria, S., Ng, B., Devitt, M.L., Babb, J.S., Kawashima, N., Liebes, L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58 (2004), 862–870.
48. [48] Pilones, K.A., Kawashima, N., Yang, A.M., et al. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res 15 (2009), 597–606.
49. [49] Belcaid, Z., Phallen, J.A., Zeng, J., et al. Focal radiation therapy combined with 4–1BB activation and CTLA-4 blockade yields long term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One, 9, 2014, 101764.
50. [50] Zeng, J., See, A.P., Phallen, J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86 (2013), 343–349.
51. [51] Deng, L., Liang, H., Burnette, B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 (2014), 687–695.
52. [52] Dovedi, S.J., Adlard, A.L., Lipowska-Bhalla, G., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74 (2014), 5458–5468.
53. [53] Park, S.S., Dong, H., Liu, X., et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 3 (2015), 610–619.
54. [54] Patel, K.R., Lawson, D.H., Kudchadkar, R.R., Carthon, B.C., Oliver, D.E., Okwan-Duodu, D., et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 17:10 (2015 Oct), 1312–1321.
55. [55] Dewan, M.Z., Galloway, A.E., Kawashima, N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15 (2009), 5379–5388.
56. [56] Reits, E.A., Hodge, J.W., Herberts, C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 (2006), 1259–1271.
57. [57] Obeid, M., Tesniere, A., Ghiringhelli, F., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 (2007), 54–61.
58. [58] Andersson, U., Erlandsson-Harris, H., Yang, H., Tracey, K.J., HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72 (2002), 1084–1091.
59. [59] Kim, J.Y., Son, Y.O., Park, S.W., et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 38 (2006), 474–484.
60. [60] Chakraborty, M., Abrams, S.I., Camphausen, K., et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170 (2003), 6338–6347.
61. [61] Burnette, B.C., Liang, H., Lee, Y., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71 (2011), 2488–2496.
62. [62] Ishihara, H., Tsuneoka, K., Dimchev, A.B., Shikita, M., Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 133 (1993), 321–326.
63. [63] Hong, J.H., Chiang, C.S., Tsao, C.Y., Lin, P.Y., McBride, W.H., Wu, C.J., Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75 (1999), 1421–1427.
64. [64] Ohba, K., Omagari, K., Nakamura, T., Ikuno, N., Saeki, S., Matsuo, I., et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43:4 (1998), 575–577.
65. [65] Nakanishi, M., Chuma, M., Hige, S., Asaka, M., Abscopal effect on hepatocellular carcinoma. Am J Gastroenterol 103:5 (2008), 1320–1321.
66. [66] Drake, C.G., Radiation-induced immune modulation. 2011, Springer, New York, NY.
67. [67] Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
68. [68] Bernstein, M.B., Garnett, C.T., Zhang, H., et al. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 29 (2014), 153–161.
69. [69] Kachikwu, E.L., Iwamoto, K.S., Liao, Y.P., et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 81 (2011), 1128–1135.
70. [70] Twyman-SaintVictor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:7547 (2015), 373–377.
71. [71] Leavy, O., Immunotherapy: a triple blow for cancer. Nat Rev Cancer 15:5 (2015), 258–259.
72. [72] Cao, Y., Tsien, C.I., Shen, Z., Tatro, D.S., Ten Haken, R., Kessler, M.L., et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23 (2005), 4127–4136.
73. [73] Corso, C.D., Ali, A.N., Diaz, R., Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res 1 (2011), 390–412.
74. [74] Takeshima, T., Chamoto, K., Wakita, D., Ohkuri, T., Togashi, Y., Shirato, H., et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 70 (2010), 2697–2706.
75. [75] Smilowitz, H.M., Sasso, D., Lee, E.W., Goh, G., Micca, P.L., Dilmanian, F.A., Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy. Cancer Immunol Immunother 62:7 (2013 Jul), 1187–1197, 10.1007/s00262-013-1423-9 Epub 2013 Apr 25.
76. [76] Postow, M.A., Callahan, M.K., Barker, C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
77. [77] Reynders, K., Illidge, T., Siva, S., Chang, J.Y., De Ruysscher, D., The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41:6 (2015), 503–510.
78. [78] Liew, D.N., Kano, H., Kondziolka, D., Mathieu, D., Niranjan, A., Flickinger, J.C., et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. J Neurosurg 114 (2011), 769–779.
79. [79] Gonzalez-Martinez, J., Hernandez, L., Zamorano, L., Sloan, A., Levin, K., Lo, S., et al. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg 97 (2002), 494–498.
80. [80] Mathieu, D., Kondziolka, D., Cooper, P.B., Flickinger, J.C., Niranjan, A., Agarwala, S., et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60 (2007), 471–482.
81. [81] Muller-Brenne, T., Rudolph, B., Schmidberger, H., Successful therapy of a cerebral metastasized malign melanoma by whole-brain-radiation and therapy with ipilimumab. J Dtsch Dermatol Ges 9 (2011), 787–788.
82. [82] Bot, I., Blank, C.U., Brandsma, D., Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 259:9 (2012 Sep), 1976–1978, 10.1007/s00415-012-6488-4.
83. [83] Knisely, J.P., Yu, J.B., Flanigan, J., Sznol, M., Kluger, H.M., Chiang, V.L., Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:2 (2012 Aug), 227–233, 10.3171/2012.5.JNS111929 Epub 2012 Jun 15.
84. [84] Silk, A.W., Bassetti, M.F., West, B.T., Tsien, C.I., Lao, C.D., Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:6 (2013 Dec), 899–906, 10.1002/cam4.140 Epub 2013 Oct 10.
85. [85] Mathew, M., Tam, M., Ott, P.A., Pavlick, A.C., Rush, S.C., Donahue, B.R., et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23:3 (2013 Jun), 191–195.
86. [86] Patel, K.R., Shoukat, S., Oliver, D.E., Chowdhary, M., Rizzo, M., Lawson, D.H., et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol, 2015 May 16.
87. [87] Kiess, A.P., Wolchok, J.D., Barker, C.A., Postow, M.A., Tabar, V., Huse, J.T., et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:2 (2015 Jun 1), 368–375, 10.1016/j.ijrobp.2015.01.004 Epub 2015 Mar 5.
88. [88] Schoenfeld, J.D., Mahadevan, A., Floyd, S.R., Dyer, M.A., Catalano, P.J., Alexander, B.M., et al. Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer, 15(3), 2015 Dec, 50, 10.1186/s40425-015-0095-8 eCollection 2015.
89. [89] Grimaldi, A.M., Simeone, E., Giannarelli, D., Muto, P., Falivene, S., Borzillo, V., et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology, 14(3), 2014 May, e28780 eCollection 2014.
90. [90] Tazi, K., Hathaway, A., Chiuzan, C., Shirai, K., Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4:1 (2015 Jan), 1–6, 10.1002/cam4.315 Epub 2014 Aug 28.
91. [91] Ahmed, K.A., Stallworth, D.G., Kim, Y., Johnstone, P.A., Harrison, L.B., Caudell, J.J., et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:3 (2016 Mar), 434–441.
92. [92] Szeifert, G.T., Atteberry, D.S., Kondziolka, D., Levivier, M., Lunsford, L.D., Cerebral metastases pathology after radiosurgery: a multicenter study. Cancer 106 (2006), 2672–2681.
93. [93] Szeifert, G.T., Kondziolka, D., Levivier, M., Lunsford, L.D., Histopathology of brain metastases after radiosurgery. Prog Neurol Surg 25 (2012), 30–38.
94. [94] Rauch, P.J., Park, H.S., Knisely, J.P., Chiang, V.L., Vortmeyer, A.O., Delayed radiation-induced vasculitic leukoencephalopathy. Int J Radiat Oncol Biol Phys 83 (2012), 369–375.
95. [95] Chin, L.S., Ma, L., DiBiase, S., Radiation necrosis following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow up. J Neurosurg 94 (2001), 899–904.
96. [96] Minniti, G., Clarke, E., Lanzetta, G., Osti, M.F., Trasimeni, G., Bozzao, A., et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol, 6, 2011, 48.
97. [97] Du Four, S., Hong, A., Chan, M., et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med, 2014, 2014, 417913.
98. [98] Khoja, L., Kurtz, G., Bernstein, M., et al. Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: does an enhanced immune response induce radionecrosis (RN)?. Proc Am Soc Clin Oncol, 33(suppl), 2015 abstr e20019.
99. [99] Colaco, R.J., Martin, P., Kluger, H.M., Yu, J.B., Chiang, V.L., Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. J Neurosurg 6 (2015 Nov), 1–7.